JP2010526153A5 - - Google Patents

Download PDF

Info

Publication number
JP2010526153A5
JP2010526153A5 JP2010507601A JP2010507601A JP2010526153A5 JP 2010526153 A5 JP2010526153 A5 JP 2010526153A5 JP 2010507601 A JP2010507601 A JP 2010507601A JP 2010507601 A JP2010507601 A JP 2010507601A JP 2010526153 A5 JP2010526153 A5 JP 2010526153A5
Authority
JP
Japan
Prior art keywords
antisense nucleic
antibody
seq
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010507601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526153A (ja
JP5924863B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/062789 external-priority patent/WO2008137901A2/en
Publication of JP2010526153A publication Critical patent/JP2010526153A/ja
Publication of JP2010526153A5 publication Critical patent/JP2010526153A5/ja
Application granted granted Critical
Publication of JP5924863B2 publication Critical patent/JP5924863B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010507601A 2007-05-06 2008-05-06 Gi症候群及び移植片対宿主病を治療及び予防する方法 Active JP5924863B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91629807P 2007-05-06 2007-05-06
US60/916,298 2007-05-06
PCT/US2008/062789 WO2008137901A2 (en) 2007-05-06 2008-05-06 Methods for treating and preventing gi syndrome and graft versus host disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015256345A Division JP6251234B2 (ja) 2007-05-06 2015-12-28 Gi症候群及び移植片対宿主病を治療及び予防する方法

Publications (3)

Publication Number Publication Date
JP2010526153A JP2010526153A (ja) 2010-07-29
JP2010526153A5 true JP2010526153A5 (OSRAM) 2011-06-23
JP5924863B2 JP5924863B2 (ja) 2016-05-25

Family

ID=39944232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010507601A Active JP5924863B2 (ja) 2007-05-06 2008-05-06 Gi症候群及び移植片対宿主病を治療及び予防する方法
JP2015256345A Active JP6251234B2 (ja) 2007-05-06 2015-12-28 Gi症候群及び移植片対宿主病を治療及び予防する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015256345A Active JP6251234B2 (ja) 2007-05-06 2015-12-28 Gi症候群及び移植片対宿主病を治療及び予防する方法

Country Status (6)

Country Link
US (6) US8562993B2 (OSRAM)
EP (1) EP2152287B1 (OSRAM)
JP (2) JP5924863B2 (OSRAM)
AU (1) AU2008247368B2 (OSRAM)
CA (1) CA2686722C (OSRAM)
WO (1) WO2008137901A2 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152287B1 (en) 2007-05-06 2014-04-02 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
US20100255514A1 (en) * 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
US9186405B2 (en) * 2007-08-16 2015-11-17 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
US20130203081A1 (en) * 2010-04-13 2013-08-08 Janusz Rak Tumor cell-derived microvesicles
DK2854850T3 (da) * 2012-05-25 2021-08-30 Sloan Kettering Inst Cancer Res Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
MX391141B (es) 2014-08-07 2025-03-21 Memorial Sloan Kettering Cancer Center Anticuerpos anti-ceramida.
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL284985B2 (en) * 2015-02-18 2023-03-01 Enlivex Therapeutics R& D Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
CA2982452A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
WO2017119988A2 (en) * 2015-12-10 2017-07-13 Memorial Sloan Kettering Cancer Center Radioprotection by wnt activation
US11730761B2 (en) 2016-02-18 2023-08-22 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US20200108091A1 (en) * 2017-04-17 2020-04-09 Memorial Sloan-Kettering Cancer Center Gut-protective effect of rig-1/mavs and sting activation
US20200362057A1 (en) * 2019-05-16 2020-11-19 Snake River Bioscience, Inc. Compositions and methods for the treatment of major depressive disorder
US10975169B1 (en) 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
CN112255221A (zh) * 2020-10-16 2021-01-22 航科中投生物技术(北京)有限公司 一种生物防护过滤介质浓度及喷涂效果的比色鉴定方法
IL305920A (en) * 2021-03-16 2023-11-01 Memorial Sloan Kettering Cancer Center Wound healing enhancement with anti-ceramide antibodies
US20240180920A1 (en) * 2021-03-23 2024-06-06 Spinogenix, Inc. Certain fascin binding compounds for spinogenesis
WO2025076313A1 (en) * 2023-10-04 2025-04-10 Memorial Sloan-Kettering Cancer Center Combination administration of bone marrow and anti-ceramide antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
JPH02128697A (ja) * 1988-11-09 1990-05-17 Hoechst Japan Ltd 抗フコシルセラミドモノクローナル抗体
US5643602A (en) 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
US5851548A (en) 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
CA2262870C (en) 1996-04-04 2008-01-29 Cilag Ag Liposome-based topical vitamin d formulation
WO1998019167A2 (en) 1996-10-29 1998-05-07 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
AU2002211681A1 (en) * 2000-10-12 2002-04-22 Curagen Corporation Proteins and nucleic acids encoding same
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
EP1660008A2 (en) 2003-05-09 2006-05-31 Curagen Corporation Therapeutic use of g53135-05(fgf-20) in radiation protection
KR100565437B1 (ko) 2003-07-31 2006-03-30 중앙대학교 산학협력단 신규한 스핑고마이엘리나제 효소, 그에 대한 항체, 안티센스 및 제조방법
US20060280738A1 (en) * 2005-06-08 2006-12-14 Tedder Thomas F Anti-CD19 antibody therapy for transplantation
CN101421393B (zh) 2006-02-14 2013-08-14 塞勒兰特治疗公司 提高造血干细胞植入的方法和组合物
EP2152287B1 (en) 2007-05-06 2014-04-02 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease

Similar Documents

Publication Publication Date Title
JP2010526153A5 (OSRAM)
Vacas et al. High-mobility group box 1 protein initiates postoperative cognitive decline by engaging bone marrow-derived macrophages
JP2020040969A5 (OSRAM)
JP2012029693A5 (OSRAM)
KR100883078B1 (ko) 항-tnf 항체, 조성물, 방법 및 용도
CN105683377B (zh) 呼吸疾病相关基因特异性siRNA、含有siRNA的双螺旋寡RNA结构、含有它们的组合物用于预防或治疗呼吸疾病
CN102596992B (zh) 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
DK2513146T3 (en) Antibodies against ROR1 capable of inducing cell death by CLL
Berg Lessons from animal models of arthritis over the past decade
KR20060054174A (ko) 항-아밀로이드 항체, 조성물, 방법 및 용도
JP2005512522A (ja) Il−13ムテインタンパク質、抗体、組成物、方法および使用
HRP20161450T1 (hr) Stabilizirana varijanta aktivinskog receptora iib
KR20100075639A (ko) 인간 항-아밀로이드 항체, 조성물, 방법 및 용도
KR20120089346A (ko) 높은 차단 활성을 갖는 항-C5a 결합 부분
Tian et al. Three TNFR-binding domains of PGRN act independently in inhibition of TNFα binding and activity
JP2012518420A5 (OSRAM)
JP2010533171A5 (OSRAM)
JP2010516290A5 (OSRAM)
CN101415439A (zh) Glp-1激动剂、组合物、方法和用途
JP2019088329A5 (OSRAM)
JP2013107899A5 (OSRAM)
Momcilović et al. CXCL12 in control of neuroinflammation
RU2015120365A (ru) Ингибирующие олигонуклеотиды и их применение
JP2013504603A5 (OSRAM)
JP7066669B2 (ja) 炎症性関節疾患の治療方法